Skip to main navigation

Investors

News Archive
Past Events and Presentations
Stock History

News Archive

News Archive

Items Per Page

Year

Dec 29, 2017

Biocon and Mylan's Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through their Partner Libbs

Dec 20, 2017

Mylan to Present at the 36th Annual J.P. Morgan Healthcare Conference

Dec 20, 2017

Mylan to Present at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top

Dec 14, 2017

Mylan Announces the U.S. Patent and Trademark Appeal Board Institutes Inter Partes Review Proceedings on All Claims Against Sanofi's Lantus® Patents

Dec 11, 2017

Teva Dismisses Litigation After Mylan Wins U.S. Court Ruling Related to Teva's Cold Filtration Patents for Copaxone® 40 mg/mL

Dec 04, 2017

Mylan and Aspen Announce Launch of Generic Busulfex® Injection

Dec 01, 2017

U.S. FDA Approves Mylan and Biocon's Ogivri™, the First Biosimilar for Trastuzumab, for the Treatment of HER2-Positive Breast and Gastric Cancers

Dec 01, 2017

FDA Approval of Heparin Sodium Injection Continues to Demonstrate Mylan's Deep Expertise in Developing Complex Products

Nov 30, 2017

European Medicines Agency Accepts Marketing Authorization Applications for Mylan and Biocon's Proposed Biosimilars Trastuzumab and Pegfilgrastim

Nov 20, 2017

Mylan to Present at Evercore ISI Inaugural Biopharma Catalyst/Deep Dive Conference

Pagination

First page
Previous page
…
Page 13
Page 14
Page 15
Page 16
Current page 17
Page 18
Page 19
Page 20
Page 21
…
Next page
Last page

Share

Utility Nav

Privacy Statement
Terms and Conditions

©2024 Mylan N.V. All rights reserved. The Mylan logo is a registered trademark of Mylan Inc.